Sapelizumab is a humanized monoclonal antibody antagonist of the interleukin-6 receptor (IL-6R/CD126), engineered with huIgG2 and hukappa chains. It is utilized in research for neuromyelitis optica spectrum disorders (NMOSD), supporting both in vitro mechanistic studies and in vivo preclinical models of autoimmune and inflammatory conditions.
Concentration:
15.081 mg/mL
Molecular Weight:
~150 kDa
Purity:
97.71% (May vary between batches)
Target:
IL Receptor,Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted